Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant

(2013) Grace Chen et al.   CLINICAL DRUG INVESTIGATION

A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition

(2013) E L Theunissen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Serotonergic Drugs for Depression and Beyond

(2013) Stephen M. Stahl et al.   CURRENT DRUG TARGETS

5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects

(2013) Per Stenkrona et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

(2013) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed

(2013) L. Citrome et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed

(2013) Leslie Citrome et al.   JOURNAL OF AFFECTIVE DISORDERS

Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice

(2013) Jean-Philippe Guilloux et al.   NEUROPHARMACOLOGY

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats

(2013) Arne Mørk et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

(2012) David S. Baldwin et al.   CURRENT MEDICAL RESEARCH AND OPINION

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

(2012) Atul R. Mahableshwarkar et al.   CURRENT MEDICAL RESEARCH AND OPINION

Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States

(2012) Anthony J. Rothschild et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial

(2012) Leszek Bidzan et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—A rat microdialysis and electrophysiology study

(2012) Alan L. Pehrson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder

(2012) David S. Baldwin et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

(2012) Cornelius Katona et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

(2012) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptor antagonism

(2012) Cécile Bétry et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder

(2012) Rakesh Jain et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder

(2012) Neven Henigsberg et al.   JOURNAL OF CLINICAL PSYCHIATRY

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

(2012) Jean-Philippe Boulenger et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects

(2011) Johan Areberg et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)

(2011) David S. Baldwin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

(2011) Enric Alvarez et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

(2011) Benny Bang-Andersen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

(2010) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Antidepressants and Body Weight

(2010) Alessandro Serretti et al.   JOURNAL OF CLINICAL PSYCHIATRY

Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

(2010) Leslie Citrome   POSTGRADUATE MEDICINE

Treatment-Emergent Sexual Dysfunction Related to Antidepressants

(2009) Alessandro Serretti et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Compelling or irrelevant? Using number needed to treat can help decide

(2008) L. Citrome   ACTA PSYCHIATRICA SCANDINAVICA

Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks

(2008) Leslie Citrome et al.   Expert Review of Neurotherapeutics